<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> influences morbidity and mortality following <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> is believed to play a role in post-haemorrhagic vasospasm </plain></SENT>
<SENT sid="2" pm="."><plain>Meloxicam is a <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the effect of meloxicam on a rat femoral artery vasospasm model using the radial wall thickness and cross-sectional lumen area as parameters under light, scanning and transmission electron microscopy examination </plain></SENT>
<SENT sid="4" pm="."><plain>Rats were randomly separated into SAH, SAH+ meloxicam and control groups </plain></SENT>
<SENT sid="5" pm="."><plain>Rats in the SAH+ meloxicam group were given meloxicam at 2 mg/kg daily for 7 days </plain></SENT>
<SENT sid="6" pm="."><plain>Femoral arteries were examined by light microscopy and scanning and transmission electron microscopy, and for morphometric analysis </plain></SENT>
<SENT sid="7" pm="."><plain>A statistically significant difference (p&lt;0.001) was detected between the SAH and SAH+ meloxicam groups </plain></SENT>
<SENT sid="8" pm="."><plain>Meloxicam treatment reduced ultrastructural and morphometric vasospastic changes </plain></SENT>
<SENT sid="9" pm="."><plain>These findings support the hypothesis that <z:mp ids='MP_0001845'>inflammation</z:mp> may play a role in the pathophysiologyical pathways of post-haemorrhagic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>